Have a feature idea you'd love to see implemented?
Let us know!
BIOR Biora Therapeutics Inc
Price (delayed)
$0.5303
Market cap
$19.34M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.18
Enterprise value
$59.69M
Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine.
Highlights
Biora Therapeutics's debt has shrunk by 64% YoY
BIOR's gross profit has soared by 58% QoQ
The company's net income has shrunk by 60% YoY but it rose by 22% QoQ
BIOR's quick ratio has dropped by 83% year-on-year and by 43% since the previous quarter
Key stats
What are the main financial stats of BIOR
Market
Valuations
Earnings
Shares outstanding
36.47M
Market cap
$19.34M
Enterprise value
$59.69M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
22.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
69.41
Revenue
$860,000
EBIT
-$78.8M
EBITDA
-$78.35M
Free cash flow
-$48.47M
Per share
Balance sheet
Liquidity
EPS
-$4.18
Free cash flow per share
-$1.36
Book value per share
-$2.49
Revenue per share
$0.02
TBVPS
$0.34
Total assets
$18.26M
Total liabilities
$107.59M
Debt
$45.68M
Equity
-$89.32M
Working capital
-$36.79M
Debt to equity
-0.51
Current ratio
0.2
Quick ratio
0.12
Net debt/EBITDA
-0.52
Margins
Efficiency
Dividend
EBITDA margin
-9,110.1%
Gross margin
100%
Net margin
-10,068.7%
Operating margin
-7,903.1%
Return on assets
-323.2%
Return on equity
N/A
Return on invested capital
-1,195.5%
Return on capital employed
N/A
Return on sales
-9,163.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BIOR stock price
How has the Biora Therapeutics stock price performed over time
Intraday
-1.92%
1 week
6.06%
1 month
-18.39%
1 year
-74.26%
YTD
-60.72%
QTD
5.72%
Financial performance
How have Biora Therapeutics's revenue and profit performed over time
Revenue
$860,000
Gross profit
$860,000
Operating income
-$67.97M
Net income
-$86.59M
Gross margin
100%
Net margin
-10,068.7%
The operating margin has soared by 87% YoY and by 36% from the previous quarter
Biora Therapeutics's net margin has surged by 82% YoY and by 51% QoQ
The company's net income has shrunk by 60% YoY but it rose by 22% QoQ
BIOR's gross profit has soared by 58% QoQ
Growth
What is Biora Therapeutics's growth rate over time
Valuation
What is Biora Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
22.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
69.41
The EPS has grown by 28% from the previous quarter and by 23% YoY
The equity is up by 26% year-on-year and by 11% since the previous quarter
The P/S is 99% lower than the last 4 quarters average of 1805.4 and 97% lower than the 5-year quarterly average of 632.2
The revenue has soared by 58% from the previous quarter
Efficiency
How efficient is Biora Therapeutics business performance
The ROS has soared by 79% YoY and by 51% from the previous quarter
Dividends
What is BIOR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BIOR.
Financial health
How did Biora Therapeutics financials performed over time
Biora Therapeutics's total assets is 83% less than its total liabilities
BIOR's quick ratio has dropped by 83% year-on-year and by 43% since the previous quarter
The company's current ratio has shrunk by 78% YoY and by 29% QoQ
Biora Therapeutics's debt is 151% higher than its equity
Biora Therapeutics's debt has shrunk by 64% YoY
The debt to equity has surged by 52% year-on-year but it has declined by 13% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.